Article thumbnail

Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases

By Orestes E. Solis, Rupal I. Mehta, Albert Lai, Rashi I. Mehta, Lama O. Farchoukh, Richard M. Green, Jerry C. Cheng, Sathima Natarajan, Harry V. Vinters, Timothy Cloughesy and William H. Yong


Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a mixed glio-neuronal neoplasm recently codified by the World Health Organization WHO Classification of Central Nervous System (CNS) Tumors (2007). To date, 43 cases have been described in the literature; most occurring in the fourth ventricle region. We report the fourth case involving the pineal region in a 16-year-old female with signs of increased intracranial pressure (ICP). A stereotactic biopsy of the mass was followed by a debulking procedure. Both specimens revealed classic RGNT histology. The patient had stable scans 7 months post-resection. The clinical, radiological and histopathologic features of the previously described 43 cases are reviewed along with our illustrative case. Mean age of patients was 30 ± 12.8 years with 1.9:1 female to male ratio. The most common presenting signs related to increased ICP and posterior fossa involvement, including: headache (62.8%), ataxia (39.5%) and vomiting and vertigo (both 16.3%). This tumor usually presents with cystic changes (54.5%) with focal enhancement (60.9%) and hydrocephalus (43.2%). Microcalcifications and satellite lesions were common radiographic observations. All reported cases had the classic biphasic pattern. Rosenthal fibers and eosinophilic granular bodies are each present in approximately two thirds of cases. Ki-67 labeling index is consistently low (mean (%): 1.8 ± 0.75 SD). The isocitrate dehydrogenase 1 or 2 mutation found in low grade diffuse gliomas is not identified in this RGNT case. Reported outcome is nearly uniformly excellent after complete or subtotal resection. A solitary report of recurrence after 10 years and the limited experience with this entity suggest that long term follow up is advisable

Topics: Case Report
Publisher: Springer US
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2010). A
  2. A et al (2006) Mixed glioneuronal tumour of the fourth ventricle with prominent rosette formation.
  3. A et al (2007) Rosette-forming glioneuronal tumor of the fourth ventricle: report of two cases with a differential diagnostic overview.
  4. (2002). A rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysembryoplastic neuroepithelial tumor?
  5. (2009). A rosette-forming glioneuronal tumor of the spinal cord: the first case of a rosette-forming glioneuronal tumor originating from the spinal cord.
  6. (2008). An integrated genomic analysis of human glioblastoma multiforme.
  7. (2008). Analysis of the IDH1 codon 132 mutation in brain tumors.
  8. (2008). Clinicoradiological features of rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle: report of four cases and literature review.
  9. (2009). Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
  10. (2009). Cytology is a useful toolforthediagnosisofrosette-formingglioneuronaltumourofthe fourthventricle:areportoftwocases.Cytopathologydoi:10.1111/
  11. (2009). Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalinfixed,paraffin-embeddedgliomatissues.JNeuropatholExpNeurol
  12. (1995). Dysembryoplasticneuroepithelialtumourofthecerebellum.ActaNeuropathol (Berl)
  13. (2005). Ependymoma with neuropil-likeislands:acasereportwithdiagnosticandhistogenetic implications.
  14. (2006). Fourth ventricle rosetteforming glioneuronal tumor: case report.
  15. (2002). Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors.
  16. (2009). IDH1 and IDH2 mutations in gliomas.
  17. (2009). IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
  18. (2011). Ketterling RP et al (2009) Rosette forming glioneuronal tumor: report of a chiasmal-optic nerve example in neurofibromatosis type 1: special pathology report.
  19. Kho AT et al (2004) The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
  20. Kocialkowski L et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastoma.
  21. Kuo YH et al (2008) The ‘rosette-forming glioneuronaltumor’ofthefourthventricle.Neuropathology29(3):
  22. (2005). Mixed neuronal glial tumor of the fourth ventricle and successful treatment of postoperative mutism with bromocriptine: case report.
  23. (2002). Oligodendrogliomas neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications.
  24. Pompucci A et al (2005) Rosetteforming glioneuronal tumour of the fourth ventricle: report of a case with clinical and surgical implications.
  25. (2009). Rosette forming glioneuronal tumor pineal gland and tectum: an intraoperative diagnosis on smear preparation. Diagn Cytopathol doi:
  26. (2009). Rosette-forming glioneuronal tumor of the fourth ventricle with previous intratumoural hemorrhage: case report and review of literature.
  27. (2009). Rosette-forming glioneuronal tumor: report of an unusual case with intraventricular dissemination. Acta Neuropathol doi:
  28. (2007). Rosette-forming glioneuronal tumour of the fourth ventricle. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC, Lyon,
  29. (2003). Rosette-forming glioneuronaltumorofthefourthventricle.ActaNeuropathol(Berl)
  30. (2001). Rosetted glioneuronal tumor: a case with proliferating neuronal nodules.
  31. (2007). The
  32. (2009). The expanding family of glioneuronal tumors.
  33. (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
  34. Vaz A et al (2008) Rosette-forming glioneuronal tumor: pathology case report.
  35. (2008). Veitch A
  36. (2007). Wiestler OD et al (2007) The
  37. Wong KK et al (2008) Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival.